Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRA NASDAQ:CLNN NASDAQ:ENLV NASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$3.36+6.5%$3.29$1.93▼$10.16$8.54M0.35456,266 shs97,344 shsCLNNClene$3.96+5.0%$3.56$2.28▼$6.96$32.74M0.5571,015 shs37,008 shsENLVEnlivex Therapeutics$1.23-0.4%$1.06$0.81▼$1.76$29.33M0.79102,044 shs36,628 shsSONNSonnet BioTherapeutics$7.32-15.0%$2.24$1.08▼$19.30$23.16M0.981.29 million shs1.79 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica+5.53%-6.53%-5.69%-17.97%+9.34%CLNNClene+1.89%-1.57%-14.71%+25.67%-23.06%ENLVEnlivex Therapeutics0.00%-5.38%+19.42%+42.20%-12.77%SONNSonnet BioTherapeutics-11.87%+85.56%+635.90%+583.33%+23.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRABiomerica1.1286 of 5 stars0.05.00.00.03.30.80.0CLNNClene3.4581 of 5 stars3.65.00.00.02.22.50.6ENLVEnlivex Therapeutics2.8585 of 5 stars3.73.00.00.03.30.80.6SONNSonnet BioTherapeutics3.7711 of 5 stars3.55.00.00.03.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 0.00N/AN/AN/ACLNNClene 3.17Buy$40.00910.10% UpsideENLVEnlivex Therapeutics 3.33Buy$10.00716.33% UpsideSONNSonnet BioTherapeutics 3.00Buy$20.00173.41% UpsideCurrent Analyst Ratings BreakdownLatest BMRA, CLNN, SONN, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.005/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$5.41M1.58N/AN/A$3.13 per share1.07CLNNClene$350K93.54N/AN/A($1.06) per share-3.74ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/ASONNSonnet BioTherapeutics$20K1,159.43N/AN/A($0.71) per share-10.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$5.98M-$2.32N/A∞N/A-85.42%-85.90%-61.06%8/26/2025 (Estimated)CLNNClene-$39.40M-$4.04N/AN/AN/A-8,306.00%N/A-105.11%8/6/2025 (Estimated)ENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)SONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-777.92%-271.32%8/13/2025 (Estimated)Latest BMRA, CLNN, SONN, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025SONNSonnet BioTherapeutics-$0.49N/AN/AN/AN/AN/A8/6/2025Q2 2025CLNNClene-$0.49N/AN/AN/A$0.06 millionN/A5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/13/2025Q2 2025SONNSonnet BioTherapeutics-$0.92-$0.89+$0.03-$0.89N/AN/A5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A3.762.76CLNNCleneN/A1.361.36ENLVEnlivex TherapeuticsN/A7.207.20SONNSonnet BioTherapeuticsN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%CLNNClene23.28%ENLVEnlivex Therapeutics1.02%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipBMRABiomerica15.00%CLNNClene35.30%ENLVEnlivex Therapeutics12.28%SONNSonnet BioTherapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica602.55 million2.16 millionOptionableCLNNClene1008.27 million5.35 millionOptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableSONNSonnet BioTherapeutics103.17 million3.10 millionNot OptionableBMRA, CLNN, SONN, and ENLV HeadlinesRecent News About These CompaniesSolana-based treasury model goes global as DeFi Development launches franchise4 hours ago | msn.comWLFI tokens to become tradable after World Liberty holders’ voteJuly 17 at 6:36 AM | msn.comHyperliquid Strategies Inc. plan for $583M treasury boosts HYPE priceJuly 16 at 6:41 PM | cointelegraph.comSonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE TreasuryJuly 15 at 8:58 AM | thecurrencyanalytics.comTSonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays ExuberantJuly 15 at 8:58 AM | msn.comPublic Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New DealJuly 14 at 8:35 PM | coinspeaker.comSonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.July 14 at 8:35 PM | marketwatch.comWhy did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?July 14 at 8:35 PM | tokenist.comTHyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrandJuly 14 at 8:35 PM | fxstreet.comHYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid StrategiesJuly 14 at 8:35 PM | msn.comMassive deal sends biotech stock rallying 367%July 14 at 8:35 PM | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)July 14 at 7:06 PM | globenewswire.comWhy Is Sonnet BioTherapeutics Stock Trading Higher On Monday?July 14 at 11:30 AM | benzinga.comSONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to ShareholdersJuly 14 at 8:18 AM | businesswire.comThis stock rockets 260% after $900 million mega crypto dealJuly 14 at 8:18 AM | finbold.comFSonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve StrategyJuly 14 at 6:00 AM | globenewswire.comSonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 20.7% - Still a Buy?July 8, 2025 | americanbankingnews.comSonnet BioTherapeutics Completes $2 Million Convertible Notes SaleJuly 2, 2025 | tipranks.comsonnet biotherapeutics receives nasdaq delisting noticeJune 4, 2025 | investing.comSonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development SummitMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMRA, CLNN, SONN, and ENLV Company DescriptionsBiomerica NASDAQ:BMRA$3.36 +0.21 (+6.51%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Clene NASDAQ:CLNN$3.96 +0.19 (+5.04%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Enlivex Therapeutics NASDAQ:ENLV$1.23 -0.01 (-0.41%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Sonnet BioTherapeutics NASDAQ:SONN$7.32 -1.30 (-15.04%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
